Apple's executive exodus sends a signal about its AI strategy
AI Sentiment
Positive
7/10
as of 12-08-2025 4:00pm EST
bioAffinity Technologies Inc addresses the need for noninvasive diagnosis of early-stage cancer and diseases of the lung and targeted cancer treatment. It develops proprietary noninvasive diagnostic tests and cancer therapeutics using technology that preferentially targets cancer cells and cell populations indicative of a diseased state. The company's product, CyPath Lung, is a noninvasive test for the detection of early-stage lung cancer.
| Founded: | 2014 | Country: | United States |
| Employees: | N/A | City: | SAN ANTONIO |
| Market Cap: | 6.6M | IPO Year: | 2022 |
| Target Price: | N/A | AVG Volume (30 days): | 99.0K |
| Analyst Decision: | Hold | Number of Analysts: | 1 |
| Dividend Yield: | N/A | Dividend Payout Frequency: | N/A |
| EPS: | -20.28 | EPS Growth: | N/A |
| 52 Week Low/High: | $1.25 - $46.53 | Next Earning Date: | 11-14-2025 |
| Revenue: | $6,776,739 | Revenue Growth: | -27.66% |
| Revenue Growth (this year): | -33.68% | Revenue Growth (next year): | 20.04% |
Machine learning model trained on 25+ technical indicators
Disclaimer: This prediction is generated by an AI model and should not be considered as financial advice. Always conduct your own research and consult with financial professionals before making investment decisions.
BIAF Breaking Stock News: Dive into BIAF Ticker-Specific Updates for Smart Investing
AI Sentiment
Positive
7/10
AI Sentiment
Positive
6/10
AI Sentiment
Positive
7/10
See how BIAF stacks up against similar companies in the market
Enhance your trading experience with our free tools
The information presented on this page, "BIAF bioAffinity Technologies Inc. - Stocks Price | History | Analysis", including historical data, forecasts, news, insider information, and predictions, is provided for educational purposes only. It should not be considered as financial advice or a recommendation to buy or sell any securities. Decisions regarding investments should be made only after careful consideration and consultation with a qualified financial advisor. We do not endorse or guarantee the accuracy or reliability of the information provided, and we disclaim any liability for financial losses incurred as a result of decisions made based on the information presented.